Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Covance and M2Gen® Enter into Alliance

Published: Friday, March 01, 2013
Last Updated: Friday, March 01, 2013
Bookmark and Share
Combines Covance’s comprehensive drug development capabilities with M2Gen’s innovative cancer-focused data warehouse to help accelerate development of targeted therapies for cancer patients.

Covance Inc. has announced that it has entered into an exclusive alliance and services agreement with M2Gen, a subsidiary of the Moffitt Cancer Center and leader in advancing personalized medicine by using high-quality tissue, clinical data and molecular technology to advance research for personalized cancer treatments.

Under the agreement, Covance and M2Gen will work together to offer biopharmaceutical clients the ability to match potential patients for biomarker-driven oncology trials with the right treatment or clinical trial.

In addition, Covance will become the preferred provider for M2Gen for DNA/RNA sequencing, gene expression analysis, and genotyping analysis services, which will be conducted at Covance’s genomics laboratory in Seattle, Washington.

M2Gen’s cancer-focused data warehouse, one of the largest of its kind in the world, and related specimen biorepository, links longitudinal clinical, molecular and specimen data from more than 95,000 consented patients from Moffitt Cancer Center and a consortium of 17 hospitals throughout the United States.

M2Gen uses a proprietary healthcare informatics platform to support a clinical trial matching program, which can significantly reduce the timeline for identifying suitable participants for enrollment in clinical trials and improve the design of biomarker driven trials.

"Working together, Covance and M2Gen expect to help biopharmaceutical companies accelerate their drug development programs, make better decisions, and improve their efforts to develop targeted therapies for cancer patients," said Ken Somberg, MD, Chief Medical Officer for Covance and Vice President, Clinical Development Services.

Somberg continued, "M2Gen’s database is unique in the industry, with clinical data captured and maintained over the cancer patient’s lifetime. This alliance will help us partner with sponsors as the field of personalized medicine continues to evolve, and as we work toward a common goal of bringing new life-saving medicines to patients who need them.”

“M2Gen considers Covance to be an ideal strategic partner with the goal of connecting patients to the best treatment options, including clinical trials, by accelerating the discovery and delivery of personalized medicine,” said Bill Dalton, PhD, MD, President and CEO of M2Gen.

Covance is a leader in clinical oncology and has conducted more than 130 trials across several tumor types in the past five years on behalf of biopharmaceutical sponsors.

The alliance with M2Gen will extend Covance’s personalized medicine strategy and reinforce its drug development capabilities in this key therapeutic area.

M2Gen and Moffitt Cancer Center will continue efforts to add new hospitals to their network, further expanding access to clinical data for thousands of consenting cancer patients across the United States.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos